207_Combined course Presentations

Basket trials matching patients to therapies based on molecular profiles

Primary outcome measure(s)

rogram ame

Lead organization

# Expected to accrue

Clinicaltrials.go v identifier

Design

Histology Indication

PI3K-activated solid tumors and/or hematologic malignancies BRAF V600 - mutated solid tumors and/or hematologic malignancies

IGNATURE

Novartis

NR

Metastatic

145

CBR

NCT01833169

Metastatic

12

CBR

NCT01981187

PTCH1 or SMO mutated

Metastatic

10

CBR

NCT02002689

RAS/RAF/MEK activated

Metastatic

110

CBR

NCT01885195

CDK4/6 pathway activated

Metastatic

90

CBR

NCT02187783

FGFR mutated Metastatic

70

CBR

NCT02160041